Use of Autoreactive Antibodies in Blood of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN) for Grade Distinction and Detection of Malignancy

Use of Autoreactive Antibodies in Blood of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN) for Grade Distinction and Detection of Malignancy

(1) Background: A reliable non-invasive distinction between low- and high-risk pancreatic intraductal papillary mucinous neoplasms (IPMN) is needed to effectively detect IPMN with malignant potential. This would improve preventative care and reduce the risk of developing pancreatic cancer and overtr...

Full description

Bibliographic Details
Main Authors: Niall Brindl, Henning Boekhoff, Andrea S. Bauer, Matthias M. Gaida, Hien T. Dang, Jörg Kaiser, Jörg D. Hoheisel, Klaus Felix
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
IPMN
pancreatic cancer
antibodies
protein microarray
biomarker
Online Access:https://www.mdpi.com/2072-6694/14/15/3562

Internet

https://www.mdpi.com/2072-6694/14/15/3562

Similar Items